Compare Adaptive Biotechnologies Corp (ADPT) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs PepsiCo, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $25.25 (market cap $4.04B), while PepsiCo, Inc. trades at $138.37 (market cap $188.91B). The key difference: PepsiCo, Inc. is far larger — about 46.8× Adaptive Biotechnologies Corp's market cap, and PepsiCo, Inc. pays a 4.28% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | PEP | |
|---|---|---|
Market Cap | $4.04B | $188.91B |
Sector | Health | Consumer Staples |
52-Week High | $25.45 | $170.44 |
52-Week Low | $12.30 | $134.95 |
Enterprise Value | $4.10B | $231.41B |
Dividend Yield | — | 4.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
PepsiCo (PEP) trades at $138.41, up 0.52% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $93.93B in 2025, with a net income margin of 10.78% and a P/E ratio of 18.14. Recent earnings have consistently beaten expectations, and analysts project a consensus price target of $158.79. News highlights include price cuts on snacks to address consumer pushback and the cessation of a festival sponsorship.
The outlook for PEP is cautiously optimistic, supported by strong profitability and dividend payments, but faces risks from competitive pressures and price sensitivity. Upside potential exists if North American performance improves as anticipated in upcoming earnings. Investor sentiment is mixed, with a majority of analysts recommending Hold, reflecting balanced growth prospects against near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
